Literature DB >> 24674124

Current clinical coverage of Radiation Therapy Oncology Group-defined target volumes for postmastectomy radiation therapy.

Hiral P Fontanilla1, Wendy A Woodward2, Mary E Lindberg3, James E Kanke2, Gurpreet Arora2, Rosalind R Durbin2, Tse-Kuan Yu2, Lifei Zhang3, Hadley J Sharp2, Eric A Strom2, Mohammad Salehpour3, Julia White4, Thomas A Buchholz2, Lei Dong3.   

Abstract

PURPOSE: The Radiation Therapy Oncology Group (RTOG) has published consensus guidelines for contouring relevant anatomy for postmastectomy radiation therapy (RT). How these contours relate to current treatment practices is unknown. We analyzed the dose-volume histograms (DVHs) for these contours using current clinical practice at University of Texas MD Anderson Cancer Center and compared them with the proposed treatment plans to treat RTOG-defined targets to full dose. METHODS AND MATERIALS: We retrospectively analyzed treatment plans for 20 consecutive women treated with postmastectomy RT for which the treatment targets were the chest wall (CW), level III axilla (Ax3), supraclavicular (SCV), and internal mammary (IM) nodes. The RTOG consensus definitions were used to contour the following anatomic structures: CW; level I, II, and III axillary nodes (Ax1, Ax2, Ax3); SCV; IM; and heart (H). DVHs for these contours and the ipsilateral lung were generated from clinically designed treatment that had actually been delivered to each patient. For comparison regarding dose to normal tissue, new treatment plans were generated with the goal of covering 95% of the anatomic contours to 45 Gy.
RESULTS: The prescribed dose was 50 Gy in each case. The mean percent of volumes that received 45 Gy (V45) for the RTOG guideline-based contours were CW 74%, Ax1 84%, Ax2 88%, Ax3 96%, SCV 84%, and IM 80%. Mean heart V10 values were 11% for treatment of left-sided tumors and 6% for right-sided tumors. Mean ipsilateral lung V20 values were 28% for left-sided tumors and 34% for right-sided tumors. For the contour-based plans, mean V45 values were CW 94%, Ax1 95%, Ax2 97%, Ax3 98%, SCV 98%, and IM 85%. Mean heart V10 values were 14% for treatment of left-sided tumors and 12% for right-sided tumors. Mean ipsilateral lung V20 values were 32% for left-sided tumors and 45% for right-sided tumors.
CONCLUSIONS: Clinically derived treatment plans, which have proven efficacy and are the current standard, cover 74% to 96% of the anatomy-based RTOG consensus volumes to the prescription dose. This discrepancy should be considered if treatment planning protocol guidelines are designed to incorporate these new definitions.
Copyright © 2012 American Society for Radiation Oncology. All rights reserved.

Entities:  

Year:  2011        PMID: 24674124     DOI: 10.1016/j.prro.2011.10.001

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  12 in total

Review 1.  Proton Therapy for Primary Breast Cancer.

Authors:  Eugen B Hug
Journal:  Breast Care (Basel)       Date:  2018-06-15       Impact factor: 2.860

2.  Early toxicity in patients treated with postoperative proton therapy for locally advanced breast cancer.

Authors:  John J Cuaron; Brian Chon; Henry Tsai; Anuj Goenka; David DeBlois; Alice Ho; Simon Powell; Eugen Hug; Oren Cahlon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-05       Impact factor: 7.038

3.  Hypofractionated postmastectomy radiotherapy with helical tomotherapy in patients with immediate breast reconstruction: dosimetric results and acute/intermediate toxicity evaluation.

Authors:  Roberto Orecchia; Damaris Patricia Rojas; Federica Cattani; Rosalinda Ricotti; Luigi Santoro; Anna Morra; Raffaella Cambria; Rosa Luraschi; Samantha Dicuonzo; Sara Ronchi; Alessia Surgo; Veronica Dell' Acqua; Paolo Veronesi; Francesca De Lorenzi; Cristiana Fodor; Maria Cristina Leonardi; Barbara Alicja Jereczek-Fossa
Journal:  Med Oncol       Date:  2018-02-13       Impact factor: 3.064

Review 4.  Novel applications of proton therapy in breast carcinoma.

Authors:  John J Cuaron; Shannon M MacDonald; Oren Cahlon
Journal:  Chin Clin Oncol       Date:  2016-08

5.  Effect of RTOG breast/chest wall guidelines on dose-volume histogram parameters.

Authors:  Sonali Rudra; Hania A Al-Hallaq; Christine Feng; Steven J Chmura; Yasmin Hasan
Journal:  J Appl Clin Med Phys       Date:  2014-03-06       Impact factor: 2.102

6.  Study to Compare the Effect of Different Registration Methods on Patient Setup Uncertainties in Cone-beam Computed Tomography during Volumetric Modulated Arc Therapy for Breast Cancer Patients.

Authors:  P Mohandass; D Khanna; T Manoj Kumar; T Thiyagaraj; C Saravanan; Narendra Kumar Bhalla; Abhishek Puri
Journal:  J Med Phys       Date:  2018 Oct-Dec

7.  Post mastectomy linac IMRT irradiation of chest wall and regional nodes: dosimetry data and acute toxicities.

Authors:  Jinli Ma; Jiongyan Li; Jiang Xie; Jian Chen; Chuanying Zhu; Gang Cai; Zhen Zhang; Xiaomao Guo; Jiayi Chen
Journal:  Radiat Oncol       Date:  2013-04-08       Impact factor: 3.481

Review 8.  Proton Therapy for Breast Cancer: A Consensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee.

Authors:  Robert W Mutter; J Isabelle Choi; Rachel B Jimenez; Youlia M Kirova; Marcio Fagundes; Bruce G Haffty; Richard A Amos; Julie A Bradley; Peter Y Chen; Xuanfeng Ding; Antoinette M Carr; Leslie M Taylor; Mark Pankuch; Raymond B Mailhot Vega; Alice Y Ho; Petra Witt Nyström; Lisa A McGee; James J Urbanic; Oren Cahlon; John H Maduro; Shannon M MacDonald
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-05-25       Impact factor: 8.013

9.  Radiation pneumonitis and pulmonary function with lung dose-volume constraints in breast cancer irradiation.

Authors:  U Blom Goldman; M Anderson; B Wennberg; P Lind
Journal:  J Radiother Pract       Date:  2013-06-07

10.  The Lack of Consensus of International Contouring Guidelines for the Dorsal Border of the Chest Wall Clinical Target Volume: What is the Impact on Organs at Risk and Relationships to Patterns of Recurrence in the Modern Era?

Authors:  Phillip M Pifer; Robert P Bice; Geraldine M Jacobson; Kristin Lupinacci; Sushil Beriwal; Hannah W Hazard; John A Vargo
Journal:  Adv Radiat Oncol       Date:  2018-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.